

ENZON PHARMACEUTICALS, INC.

Reported by
RACKEAR ANDREW D.

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 04/05/16 for the Period Ending 03/31/16

Address	20 COMMERCE DRIVE, SUITE 135 CRANFORD, NJ 07016
Telephone	732-980-4500
CIK	0000727510
Symbol	ENZN
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Rackear Andrew D.	2. Date of Event Requiring Statement (MM/DD/YYYY) 3/31/2016	3. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS, INC. [ENZN]
(Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC., 20 COMMERCE DRIVE, SUITE 135	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CEO and Secretary /	
(Street) CRANFORD, NJ 07016	5. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
(City) (State) (Zip)		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy) (1)	(2)	1/17/2022	Common Stock	25000	\$2.64	D	

Explanation of Responses:

- (1) Options granted by Issuer pursuant to its 2011 Stock Option and Incentive Plan and qualified under Rule 16b-3(d).
- (2) The options vested in four (4) tranches. Of the 25,000 options granted, 6,250 options vested on January 17, 2013, 6,250 options vested on January 17, 2014, 6,250 options vested on January 17, 2015, and the remaining 6,250 options vested on January 17, 2016.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Rackear Andrew D. C/O ENZON PHARMACEUTICALS, INC. 20 COMMERCE DRIVE, SUITE 135 CRANFORD, NJ 07016			CEO and Secretary	

Signatures

/s/ Andrew Rackear

4/4/2016

* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.